Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling next week that could have broad consequences for their ability to sell lucrative patented medicines in the country. The Supreme Court is due to decide on April 1 whether or not an amended form of Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the recent past," said Ajay Kumar Sharma, associate director of the pharmaceutical and biotech practice at ...
Big Pharma in nervous wait for verdict on Glivec patent
If Novartis' cancer drug is denied IPR, it will be the latest in a string of causalties faced by global players such as Bayer, Pfizer and Roche